May 9, 2013
/PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced that
David C. Yeomans
, Ph.D., Chief Scientist and Founder, as well as the Director of Pain Research at
School of Medicine, gave a presentation at the American Pain Society (APS) 32
Annual Scientific Meeting on
, 2013, in
Dr. Yeomans was selected by the APS to present data on Trigemina's lead product candidate, TI-001, an intranasal oxytocin pain therapy, during the Clinical and Basic Science Data Blitz event on
Wednesday, May 8
6 PM to 8 PM ET
. The blitz was composed of innovative and compelling presentation of new research, with presenters having five minutes to present and an additional five minutes to answer questions from the audience.
"The need to share and discuss new research in pain has become increasingly important, especially when considering the impact that prescription drug abuse has had on our country in recent years," said Dr. Yeomans. "The APS Data Blitz provides researchers and physicians with valuable information on emerging therapies, like TI-001, which may one day provide a safe, non-addictive and effective solution to people suffering from chronic pain."
TI-001 is currently being evaluated in a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched Phase II clinical study, titled TRIG-05, for efficacy, tolerability and safety in patients with chronic migraine. Promising preclinical and human pilot study results suggests TI-001 could be a safe, non-narcotic form of therapy for the effective relief of chronic migraine, a debilitating condition with few treatment options.
Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina's lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.
For additional information, please visit
The Ruth Group
SOURCE Trigemina, Inc.